Home›Trial›NCT07330778
NCT07330778Phase 1RECRUITING

A Study of CDX-622 in Participants With Mild to Moderate Asthma

Study Summary

This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.

Conditions
Mild to Moderate Asthma
Interventions / Drugs
CDX-622
View on ClinicalTrials.gov ↗
Sponsor
CLDX
Celldex Therapeutics
Immuno-Oncology
C61/100
Study Details
Enrollment12 participants
Primary Completion—
Lead SponsorCelldex Therapeutics
Data Retrieved2026-04-11 04:09:37.490128+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 12 participants
Sponsor Catalyst Profile

Celldex Therapeutics (CLDX) is the sponsoring company for this trial. BiotechSign currently grades this company C (61/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

CLDX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.